StockNews.AI

N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

StockNews.AI • 1 minute

MCRBFSDCFLT
High Materiality8/10

Information

Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “C...

Original source

AI Summary

N2OFF's subsidiary, MitoCareX Bio, published a study identifying SLC25A carriers as therapeutic targets for conditions induced by spaceflight, which aligns with their research focus. Moreover, the company’s strategic expansion into renewable energy enhances overall growth prospects. These developments could positively influence NITO's future valuation.

Sentiment Rationale

The study adds scientific credibility to NITO's drug discovery efforts, similar to how breakthroughs in biotech have historically driven stock prices higher, like with companies advancing cancer therapies.

Trading Thesis

NITO presents a bullish investment opportunity due to strategic advancements in biotech and energy sectors.

Market-Moving

  • Positive study results could attract investor interest in NITO's biotech prospects.
  • NITO's renewable energy investments may enhance financial stability and growth potential.
  • Increased recognition from academic research can boost stock sentiment and appeal.
  • Sales from MitoCareX drug development may drive future revenue growth.

Key Facts

  • N2OFF's subsidiary published study on SLC25A mitochondrial carriers.
  • The study identifies therapeutic targets for spaceflight-induced dysfunctions.
  • N2OFF focuses on drug discovery targeting cancer therapies.
  • Company's solar energy investments expand in Europe with RTB strategy.
  • Research aligns with N2OFF's focus on mitochondrial biology.

Companies Mentioned

  • MitoCareX Bio Ltd (N/A): Nito's subsidiary focused on drug discovery for cancer therapeutics.
  • Solterra Energy Ltd (N/A): Introduces renewable energy projects for NITO's investment strategy.
  • Save Foods Ltd (N/A): Controls 98%, enhancing NITO's portfolio in agricultural technology.

Corporate Developments

This falls under 'Corporate Developments' as it highlights significant advancements in research and strategic investments that may drive NITO's future performance.

N2OFF Highlights Groundbreaking Research on Mitochondrial Carriers in Spaceflight Conditions

Neve Yarak, Israel – January 15, 2026 – N2OFF, Inc. (NASDAQ: NITO), a notable drug discovery company, has announced an exciting development in the field of mitochondrial research. Today, N2OFF highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (a wholly-owned subsidiary of N2OFF). This pivotal study investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for disorders linked to spaceflight conditions, including microgravity and cosmic radiation.

Key Details of the Research Study

The study, titled SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction: the ADP/ATP carrier (AAC3) as a structural case study, was published online on December 30, 2025, in the Journal of Translational Medicine (DOI: 10.1186/s12967-025-07505-z). It integrates transcriptomic data from NASA's Open Science Data Repository (OSDR), focusing on the expression of 53 SLC25A genes in several types of cells under stress conditions.

  • Cells examined include osteocytes, human bone marrow-derived mesenchymal stem cells (hBMSCs), and mouse brain tissue.
  • The analysis revealed differential regulation of various SLC25A carriers, indicating their potential role as biomarkers for mitochondrial dysfunction.
  • The study further analyzed the ADP/ATP carrier AAC3, demonstrating how structural features of carriers may be utilized to restore mitochondrial bioenergetics under stress.

Impact and Implications of the Study

This independent research was conducted in collaboration with the University of Bari “Aldo Moro” and the University of Pittsburgh. While it was not performed under MitoCareX Bio's auspices, it aligns closely with the company’s focus on mitochondrial carrier biology. MitoCareX Bio employs proprietary computational methods, including the MITOLINE™ algorithm, to model and virtually screen small-molecule modulators targeting the SLC25A family of mitochondrial carriers.

These carriers are vital to cellular energy metabolism and are essential in addressing issues related to tumor metabolic adaptation and therapy resistance, particularly in challenging cancers such as pancreatic and non-small cell lung cancer. Furthermore, they are implicated in rare hereditary disorders associated with neuromuscular degeneration, which share mechanisms with physiological changes observed in astronauts.

Expert Insights and Company Vision

Prof. Ciro Leonardo Pierri’s expertise in structural biology and mitochondrial modeling is pivotal to the foundational scientific endeavors supporting MitoCareX Bio's precision oncology pipeline.

About N2OFF Inc.

N2OFF Inc. fully owns MitoCareX Bio Ltd., a drug delivery company engaged in pioneering drug discovery, focusing on cancer therapies and other diseases through the mitochondrial SLC25 protein family. Additionally, N2OFF has adopted an investment strategy that emphasizes renewable energy assets in Europe, utilizing a Ready to Build (RTB) model. Currently, the Company is the lead investor in four solar projects across three European Union countries, introduced by its wholly-owned subsidiary, Solterra Renewable Energy Ltd.

N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company dedicated to enhancing post-harvest treatment technologies aimed at reducing pathogen contamination in fruits and vegetables. For more information, please visit www.n2off.com.

Forward-Looking Statements

This announcement contains forward-looking statements under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “anticipates,” “intends,” and similar expressions are intended to identify these statements. Forward-looking statements may address N2OFF's plans, technological advancements, business objectives, and expected future performance. Since these statements involve risks and uncertainties, actual results may differ materially. Investors are encouraged to review N2OFF's annual report on Form 10-K for further details on risks.

Contact Information

For investor relations, please contact: Michal Efraty at michal@efraty.com.

Related News